CAR T-Cell Therapy Market Analysis

The CAR T-cell therapy market is segmented by indication, by target antigen and by region. On the basis of indication, the market is further segmented into acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL) and others, out of which, the DLBCL segment is anticipated to hold the largest share in the market on account of growing cases of the condition which raise the demand for CAR T-cell therapy. The segment for multiple myeloma is another segment anticipated to observe significant growth in the market as a result of rising research and development in that area. Based on target antigen, the market is segmented into CD19, CD20, CD22, CD30, GD2 and others. Out of these, the segments for CD19 and CD20 target antigens are anticipated to hold the largest shares in the CAR T-cell therapy market. This can be attributed to the high approval rate of therapies containing these antigens.

Our in-depth analysis of the global market includes the following segments:

By Indication	Acute Lymphoblastic Leukemia [ALL] Chronic Lymphocytic Leukemia [CLL] Multiple Myeloma [MM] Diffuse Large B Cell Lymphoma [DLBCL] Others
By Target Antigen	CD19 CD20 CD22 CD30 GD2 Others

Frequently Asked Questions (FAQ)

The increasing research resulting in development of effective targeted therapies such as CAR T-cell therapy and growing cases of cancer are factors driving the market growth.

The market is anticipated to attain a CAGR of 35% over the forecast period, i.e. 2020-2028.

North America is anticipated to provide more business opportunities for growth on account of growing FDA approvals of therapies in the United States.

The major players in the market are Novartis International AG, Gilead Sciences, Inc., Pfizer Inc., Johnson & Johnson, Amgen Inc., Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Sorrento Therapeutics, Celgene Corporation and Bluebird Bio.

CAR T-Cell Therapy Market Analysis